[Form 4] Phathom Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Insider transaction summary for Phathom Pharmaceuticals (PHAT): On 09/05/2025 Robert Charles Breedlove, listed as Principal Accounting Officer and an officer/director, disposed of 461 shares of Phathom common stock at $12.09 per share to satisfy tax withholding obligations arising from the settlement of restricted stock units. After the reported sale, Mr. Breedlove beneficially owned 47,931 shares directly and 6,945.4 shares indirectly through a 401(k) account. The Form 4 was signed on 09/09/2025 and indicates the transaction code S(1) with the provided explanation that the sale was to cover tax withholding on RSU settlement.

Insights

Corporate Governance Expert

TL;DR: Routine RSU tax-withholding sale by an officer; no additional governance issues disclosed.

The filing documents a small, routine disposition of 461 shares by the Principal Accounting Officer to satisfy tax withholding tied to restricted stock unit settlement. The disclosure is limited to the single transaction type and an explanation that the sale satisfied tax withholding obligations. There is no indication of unusual trading patterns, additional derivative activity, or coordination with other reporting persons. From a governance perspective, the filing serves the compliance function required under Section 16, and the details provided are standard for RSU settlements.

Securities Analyst

TL;DR: Insider sold 461 shares at $12.09 for tax withholding; remaining holdings are modest and clearly reported.

The report shows a disposition at $12.09 per share with post-transaction direct beneficial ownership of 47,931 shares and indirect ownership of 6,945.4 shares via a 401(k). The transaction code S(1) and the explicit explanation link the sale to tax-withholding on RSU settlement, which frames the sale as non-discretionary. No cash amounts beyond the per-share price, no option exercises, and no additional purchases or sales are reported. The filing supplies the necessary transparency for investors and regulators but does not provide information affecting company fundamentals.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Breedlove Robert Charles

(Last) (First) (Middle)

C/O PHATHOM PHARMACEUTICALS, INC.

100 CAMPUS DRIVE, SUITE 102

(Street)

FLORHAM PARK NJ 07932

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Phathom Pharmaceuticals, Inc. [ PHAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/05/2025		S(1)		461	D	$12.09	47,931	D
Common Stock								6,945.4	I	By 401(k)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold to satisfy tax withholding obligations upon the settlement of restricted stock units.

	/s/ Robert Charles Breedlove	09/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Robert Charles Breedlove report on Form 4 for PHAT?

He reported a disposition of 461 shares of Phathom common stock on 09/05/2025 at a price of $12.09 per share.

Why were the 461 shares sold according to the Form 4?

The filing states the shares were sold to satisfy tax withholding obligations upon the settlement of restricted stock units.

How many PHAT shares does Breedlove beneficially own after the reported transaction?

Following the transaction he beneficially owned 47,931 shares directly and 6,945.4 shares indirectly via a 401(k) account.

What role does the reporting person hold at Phathom Pharmaceuticals?

The Form 4 identifies Robert Charles Breedlove as an Officer with the title Principal Accounting Officer and indicates he is also a director.

When was the Form 4 signed?

The Form 4 is signed by Robert Charles Breedlove on 09/09/2025.